Montelukast

SKU: orb1307782

Description

Montelukast sodium

Research Area

Neuroscience, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 151767-02-1
• MW: 608.17
• Purity: >98%
• Formula: C₃₅H₃₅ClNO₃S Na
• SMILES: C(S[C@@H](c1cc(/C=C/c2nc3c(cc2)ccc(c3)Cl)ccc1)CCc1c(cccc1)C(O)(C)C)C1(CC1)CC(=O)[O-].[Na+]
• Target: GPCR
• Solubility: Soluble in DMSO (up to 60 mg/ml), in Water (up to 30 mg/ml) or in Ethanol (up to 60 mg/ml)

Bioactivity

• In Vivo:
  Montelukast acts by binding to the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchi, thereby blocking the effects of leukotriene D4. This action prevents airway edema, smooth muscle contraction, and secretion of viscous liquids, reduces bronchoconstriction caused by leukotrienes, and diminishes inflammation occurrence.
• In Vitro:
  Administering 6 mg/kg of Montelukast once daily for 20 days significantly inhibits the increase of eosinophils in both the BAL fluid and lung tissue in mice stimulated by OVA, while also elevating the IL-5 levels in the BAL fluid. OVA stimulation leads to an upsurge in CysLT1 receptor mRNA expression but a decrease in CysLT2 receptor mRNA expression. Following OVA stimulation, Montelukast suppresses the elevated expression of CysLT1 without diminishing the expression of CysLT2.
• Cell Research:
  Nasal mucosa and polyp epithelial cells are stimulated with fetal bovine serum (FBS) with or without MK for 24 hours, and cytokine concentrations in epithelial secretions are measured by ELISA. After incubating peripheral blood eosinophils with epithelial cell-conditioned media (ECM) with or without montelukast up to 3 days, eosinophil survival is assessed by Trypan blue dye exclusion.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

MK-0476

Compound Identifiers

PubChem CID

23663996